首页>投融资
Kiyatec
C轮
Kiyatec Llc is a developer of advanced 3D cell culture technology designed to predict patient response to therapies before the treatment begins. The company's technology utilizes patients' living tumour cells to create phenotypic 3D cell-based models for drug response profiling and analyzing cell-material interactions, enabling medical practitioners to isolate effective treatments for patients having cancer and tumours.In December 2022, Kiyatec Inc closed its Series C funding round totalling US$18 million
基本信息
-
公司全称KIYATEC Inc
-
类型癌症药物开发服务和临床测试服务商
-
产业领域生物药、研发制造服务
-
公司人数15~50人
-
地址2 North Main Street Greenville South Carolina 29601; US;
-
联系电话864-502-2013
-
邮箱customer.service@kiyatec.com
-
成立时间2005-01-01
投融资
-
2022-12-12C轮1800万美元LabCorpSeae VenturesVentureSouthBruker
-
2021-04-30未透露250万美元Seae Ventures
-
2019-05-01B轮300万美元LabCorpVentureSouth
-
2012-05-23A轮未透露Nexus Medical&Technology CapitalUpstate Carolina Angel Network
- 加载更多
相关投融资企业
D轮
eGenesis Inc is a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage.In November 2019, the company had raised 100 million through series B financing
C轮
Kiyatec Llc is a developer of advanced 3D cell culture technology designed to predict patient response to therapies before the treatment begins. The company's technology utilizes patients' living tumour cells to create phenotypic 3D cell-based models for drug response profiling and analyzing cell-material interactions, enabling medical practitioners to isolate effective treatments for patients having cancer and tumours.In December 2022, Kiyatec Inc closed its Series C funding round totalling US$18 million
未透露
Kiyatec Llc is a developer of advanced 3D cell culture technology designed to predict patient response to therapies before the treatment begins. The company's technology utilizes patients' living tumour cells to create phenotypic 3D cell-based models for drug response profiling and analyzing cell-material interactions, enabling medical practitioners to isolate effective treatments for patients having cancer and tumours.In December 2022, Kiyatec Inc closed its Series C funding round totalling US$18 million